EGFRp4 Peptides: A Novel Strategy for Epidermal Growth Factor Receptor (EGFR) Inhibitor

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) is crucial in cell signaling.
• EGFR malfunction is linked to various cancers, including lung, breast, and gastric.
• Previous EGFR-specific peptide discovery methods excluded ribosome display.

Purpose of the Study:

• To discover novel EGFR-specific peptides using ribosome display.
• To characterize the binding affinity and mechanism of action of identified peptides.
• To evaluate the therapeutic potential of EGFR-targeted peptide conjugates.

Main Methods:

• Ribosome display selection against EGFR extracellular domain (ECD).
• Binding affinity assays (fluorescence polarization, surface plasmon resonance, ligand tracer).
• Molecular docking simulations.
• In vitro efficacy studies of peptide conjugates on EGFR-expressing cell lines.

Main Results:

• Identified EGFRp1 and EGFRp4 peptides via ribosome display.
• EGFRp4 demonstrated high binding affinity (nanomolar range) and positive cooperativity with EGFR ECD.
• Molecular docking revealed EGFRp4's preference for active EGFR conformations.
• EGFRp4 conjugation enhanced cyclic peptide NP1 efficacy, inhibiting EGFR-expressing cells, inducing apoptosis, and suppressing phosphorylation.

Conclusions:

• EGFRp4 is a high-affinity EGFR-targeting peptide.
• EGFRp4 exhibits a cooperative binding mechanism with active EGFR conformations.
• EGFRp4-based peptide conjugates show promise for EGFR-targeted cancer therapy, comparable to Erlotinib.